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Abstract 
Introduction: The Patient-rated Tennis Elbow Evaluation enables quantitative rating by the patient of 
pain and functional impairment associated with tennis elbow, or lateral elbow tendinopathy. When 
used as an outcome measure in trials of therapies, a Minimum Clinically Important Difference 
(MCID) value is required to interpret trial outcomes. This study aimed to calculate the MCID for a 
sample of patients diagnosed with lateral elbow tendinopathy (LET). 
Methods: The PRTEE was used as an outcome measure with participants in a trial of a novel therapy 
for LET. It was administered at baseline and after treatment, three weeks later. Score changes were 
compared to patient-rated Global Change Scores using Receiver Operating Curve analysis. MCID 
values were calculated for two different criteria of clinically important difference and the effects of 
baseline symptom severity on the MCID were investigated. 
Results: Data was available from fifty seven participants, with PRTEE scores in the range 13-81 / 100. 
For clinical significance defined as “a little better” the MCID for the total PRTEE score was 7/100 or 
22% of baseline score. For clinical significance defined as “much better” or “completely recovered”, 
the MCID was 11/100 or 37% of baseline score. The MCID value was higher for a subgroup with 
greater baseline severity. 
Conclusions: Substantial changes in the PRTEE scores are required before they can be considered 
clinically significant. Clinically significant change varies according to the baseline score. The 
instrument may be less sensitive to change when used by people who are symptomatic in their non-
dominant arm. 
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Introduction  
Tennis elbow, also known as lateral elbow tendinopathy or lateral epicondylalgia1, is a common 
musculoskeletal disorder that can cause significant pain and disability. Various assessment 
instruments are used by clinicians and researchers for monitoring the progress of the disorder and 
the effectiveness of its treatment. A combination of measures is commonly employed, addressing 
physical variables such as pain and strength, functional limitations and psychosocial factors. The 
Patient-rated Tennis Elbow Evaluation (PRTEE) is an instrument that has been developed specifically 
for use with this disorder2, and is increasingly being employed in research3-8. It takes the form of a 
15-item questionnaire, with five items addressing pain and ten concerned with functional deficit. For 
each item, the respondent uses a 0 – 10 numerical scale to rate the average pain or difficulty they 
have experienced over the previous week while carrying out various activities that are commonly 
painful in tennis elbow. The marking system ensures pain and function are weighted equally in the 
total score. Higher scores represent greater severity and the maximum score is 1009. Its particular 
strengths are its simplicity and shortness, and  its specificity to tennis elbow. Prior to its 
development, the only available patient-rated instruments were more generic, such as the 
Disabilities of the Arm, Shoulder and Hand (DASH) Questionnaire10 and variants of the SF-36 Quality 
of Life Questionnaire11.  
 
The measurement properties of the PRTEE have been evaluated in several studies. It has been 
validated by findings of moderate to excellent correlation with more established scales such as the 
DASH and SF-3612-16, although a recent study found only poor to moderate correlation between 
individual items in the PRTEE and other comparable measures, including visual analogue pain ratings 
and items on the EuroQol Scale17. Several studies using English and other language versions of the 
PRTEE with people with tennis elbow have concluded that its test-retest reliability is excellent, with 
correlation coefficients for the total score and the pain and function sub-scores being greater than 
0.9 in most cases12-16, 18. Unfortunately the credibility of several of these studies is undermined by 
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the use of short test-retest intervals - between 30 minutes and two days. Such intervals run the risk 
of introducing bias, since respondents are likely to remember their previous scores. Calculated 
reliability indices may thereby be inflated. A more recent study used a four-week test-retest period 
and calculated Intraclass Correlation Coefficient values of 0.81 for the pain sub-score and 0.76 for 
the total score17, still reasonable although not excellent. Such values are probably more reflective of 
reliability in clinical trials using the PRTEE, where inter-test intervals of several weeks are common. 
The responsiveness of the PRTEE – its capacity to detect change – has received little attention in the 
literature, although it is a key property in interpreting score changes19.  
 
Two dimensions of responsiveness are of interest. The Minimum Detectable Change (MDC) 
represents the smallest change in score that likely reflects true change rather than measurement 
error alone20. Knowledge of this quantity is helpful in establishing sample sizes required for clinical 
trials. It can be calculated from reliability data21, but has not been reported in published PRTEE 
reliability studies. The Minimum Clinically Important Difference (MCID) is the minimum change that 
would be interpreted as meaningful and worthwhile22. Knowing the MCID value for a particular 
instrument helps both clinicians and researchers to judge whether treatment is having a useful 
effect on the variables of interest. In the evaluation of patient-rated measures like the PRTEE, it is 
the patient’s opinion that should be given most weight in defining “meaningful and worthwhile”23. 
There are various approaches to the determination of MCID values but an anchor based-method, 
involving comparison of scores on the measure of interest with those provided by a different but 
related measure, has been recommended23, 24. Global change ratings are commonly adopted as the 
anchor referent because they can readily be used to define clinical significance, but this approach 
has not previously been employed to determine the responsiveness of the PRTEE. Therefore we 
conducted a study with the aim of determining the MCID of the PRTEE when used as an outcome 
measure with a sample of individuals with tennis elbow. Since MCID values may vary according to 
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baseline status on the variables of interest, we also investigated whether this was the case when 
using the PRTEE. 
 
Materials and Methods 
This study formed part of a prospective trial of microcurrent, a subsensory electric current applied to 
promote analgesia and tissue healing. The trial involved the application of four different forms of 
microcurrent to compare their effectiveness (manuscript in preparation), and was approved by the 
authors’ Institutional Ethics Committee. Participants were recruited via publicity in local offices, 
nearby sports clubs and local media, and all provided informed consent before enrolment. Eligible 
participants were over 18 years of age, able to complete the questionnaire, experiencing lateral 
elbow pain for at least 3 months with no significant change in the previous month, and had a clinical 
diagnosis of tennis elbow made by a physiotherapist. The diagnosis was based on a history of lateral 
elbow pain exacerbated by gripping activities, and tenderness at the lateral epicondyle coupled with 
lateral elbow pain on at least one of the following: resisted middle finger extension, resisted wrist 
extension or the chair-lift test4, 25. This was supplemented by sonographic assessment of the 
common extensor tendon, conducted by the physiotherapist who had been trained for the 
purpose26. Tendinopathy was confirmed by the presence of thickening, hypoechoic areas, fibrillar 
disruption or calcification in the tendon27, 28. Concomitant upper limb disorders did not exclude 
participation so long as the clinical and sonographic signs of tennis elbow were present. 
 
Participants were instructed in the use of the PRTEE following the guidance provided in the user 
manual9. Minor changes were made to the wording of some questions to enhance comprehensibility 
in the British context. In section 2, the words “coffee” and “milk” were removed, “pants” was 
replaced by “trousers”, and “washcloth or wet towel” were replaced by “wet cloth”. For the 
purposes of this study, participants were asked to complete the questionnaire twice, three weeks 
apart, during which time they received treatment for their tennis elbow. The treatment consisted of 
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daily application of microcurrent to the lateral elbow via adherent electrodes. At second assessment 
participants were also asked to rate any change in their condition since first assessment, using a six 
point global change score (GCS), with the terms “much worse”, “a little worse”, “unchanged”, “a 
little better”, “much better”, “completely recovered” as its descriptors. For analytical purposes, 
these were converted to scores of -2, -1, 0 , 1, 2 and 3 respectively. Demographic and medical 
history data were also collected at baseline. 
 
Data analysis 
Absolute and percentage changes in PRTEE total and subscale scores between the assessments were 
calculated. These were compared with corresponding GCS values graphically and using the 
Spearman rank correlation coefficient, since the GCS is an ordinal scale. This was done to establish 
whether scores on the two scales were related, which is necessary if the GCS is to be used as the 
external comparator for the PRTEE scores23. The MCID for the instrument was then determined 
using the GCS as an anchor and determining the group average change in PRTEE score corresponding 
to two different definitions of clinical significance: CGS = 1 (“a little better”) and GCS = 2 (“much 
better”). The specificity and sensitivity of the change score for these classifications were examined 
using a Receiver Operator Characteristic (ROC) curve analysis, and the MCID was estimated for the 
best match of sensitivity and specificity29. Area under the curve (AUC) analysis was conducted to 
gauge how well the PRTEE discriminates between those whose score change is clinically significant 
from those for whom it is not. To investigate the potential effect of baseline severity on the MCID, 
separate analyses were conducted on subgroups defined by a baseline total PRTEE score of  <40 and 
≥ 40. This cut-off was selected post-hoc to ensure reasonably sized sub-groups for this sample. All 
statistical tests were conducted using SPSS 17 (SPSS Inc, Chicago) with significance set at p≤0.05. 
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Results 
Sixty people diagnosed with tennis elbow underwent baseline assessment. Of these, one withdrew 
before second assessment and two had missing questionnaires due to administrative error, leaving 
data from 57 people for analysis. Their baseline characteristics are presented in Table 1. PRTEE 
subscale and total scores covered a wide range of the possible score values. Eleven participants were 
symptomatic in their non-dominant arm. Five of these reported bilateral symptoms and had baseline 
total scores in the range 34-76/100, representing a range of severities. 
 
At second assessment, global change scores indicated that three participants judged their condition 
to have deteriorated, 18 said it was unchanged, 19 reported it was a little better and 17 said it was 
much better. Chart 1 is a box and whisker plot showing the median and inter-quartile range of 
change in PRTEE total scores corresponding to each global change score. The scores of the two 
outliers were checked and found correct. As the plot illustrates, the spread of score changes 
increased with higher GCS values; however, the spread of percentage score changes varied much 
less between GCS scores. Absolute and percentage changes in pain, function and total scores all 
showed significant (p<0.001) moderate correlation with global change scores, with Spearman’s rho 
between -0.54 and -0.66, the highest values being for the total score changes. The negative 
correlations are a consequence of the way score changes are calculated: by subtraction of baseline 
from follow-up values. Clinical improvements therefore corresponded to negative change values.  
Changes in pain and function subscale scores were significantly correlated (Spearman’s rho = 0.63, 
p<0.01). 
 
Table 2 presents data from the ROC curve analysis, conducted using the two definitions of clinically 
significant  change and estimating a cut-off value for each score where sensitivity and specificity are 
approximately equal.  
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AUC values greater than 0.8 are considered to indicate excellent discriminatory capacity22, and all 
scale and sub-scale changes met this criterion except for percentage changes in the function 
subscale score, which approached it. As would be expected, larger absolute and percentage changes 
in scores are required to meet the stricter criterion for the MCID, with score changes of 35-40% of 
the baseline value being required to be considered clinically significant. Table 3 presents data from 
the sub-group analysis, with cut-off values for total score where clinical significance is defined as 
GCS=2. Both absolute and percentage changes in total score had AUC values greater than 0.8. 
 
A number or participants volunteered comments about use of the questionnaire. A common 
comment is that it was problematic to score “difficulty” and “pain” as separate entities because the 
difficulty was seen as entirely a consequence of pain rather than, say, weakness; so they were 
inclined to see the two subscales as addressing the same question. Some also reported that, since 
they were either symptomatic on the non-dominant side or had learned to use the non-symptomatic 
limb for activities identified in the questionnaire, they did not feel limited in the activities specified.  
 
Discussion 
Since pain and functional limitations are the most common consequences of tennis elbow, it is 
reasonable to expect changes in their PRTEE scores to correlate with the individual’s overall rating of 
the condition. A correlation threshold of 0.30 – 0.35  between a patient-rated outcome and an 
anchor has been recommended for estimating MCIDs, and this criterion was met in this study23. 
However, the correlation is only moderate, suggesting that factors other than those addressed by 
the questionnaire are involved in the patient’s global impression. This interpretation is supported by 
the relatively large changes in PRTEE scores that are required before the individual considers that 
significant improvement has occurred. It may also be relevant that more than 20% of participants in 
this study either were  symptomatic in the non-dominant arm, or reported compensatory use of the 
unaffected arm. A consequence of this is that changes in the condition may not have been 
9 
accompanied by commensurate changes in rating of those particular items by these individuals, in 
which case the instrument is less sensitive to change for this sub-group.  The five participants who 
reported bilateral symptoms had a variety of global change scores and inspection of their data 
suggested that these were commensurate with their PRTEE score changes. Hence, the questionnaire 
appeared valid for use with this sub-group. 
  
The difficulty that was reported by some participants in distinguishing ratings of pain and difficulty 
attempting tasks is reflected in the significant correlation between changes in the pain and function 
subscale scores. Pain and function scores were also significantly correlated at each time point. This 
suggests that respondents largely equated the two constructs and casts some doubt on the value of 
modelling them as distinct metrics in a patient-rated measure. It may be that separate rating of 
functional problems is worthwhile when weakness is a significant feature of the presentation. 
 
The primary function of the MCID is to inform interpretation of group mean values, for example in 
clinical trials of treatment effectiveness. This study indicates that substantial changes in group mean 
PRTEE scores are required before a clinically significant change can be assumed to have occurred, 
even using the more liberal criterion of “a little better”. The more stringent criterion of “much 
better” requires falls of the order of 35-40% of baseline scores to be confident that a desirable level 
of improvement has occurred. Where a study reports a statistically significant difference between  
two treatments, but the actual change in the more effective treatment group mean PRTEE score is 
less than 35%, the value of the treatment remains open to question. 
 
The sub-group analysis confirms that the absolute score change considered clinically significant 
depends on the baseline severity of the condition. Sub-groups with milder symptoms require 
considerably smaller PRTEE score changes than those with more severe presentations in order to 
consider that significant improvements have occurred. However, percentage changes in scores that 
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are regarded as clinically significant are similar between severity sub-groups. This finding is 
consistent with studies of numerical pain scales, which have concluded that changes of 30-35% of 
baseline score are clinically significant30, 31. 
 
The Minimum Detectable Difference can be determined using test-retest reliability data21, although 
most reliability studies have not reported it for the PRTEE. Calculations using data from three 
studies13, 16, 18 suggests that the MDD for the total score lies in the range 8-12 points, meaning that 
the score must change by at least this much to be confidently interpreted as real, and not 
attributable to random error alone. These values exceed the liberal MCID value for milder 
presentations, and so suggest that the test-retest reliability of the instrument may limit its use for 
detecting clinically significant change in this group. 
 
There were several potential limitations in this study. The changes made to the wording of some 
items in the questionnaire may have influenced its measurement properties. Indeed this was the 
intention: we felt that the relatively minor changes would enhance understanding and consistent 
interpretation of the questions. This might have produced different findings than if the standard 
version had been used, although we suspect that the differences would be minor. The study sample 
size was not determined prospectively because the investigation drew data from a broader pilot 
study. This was a pragmatic pilot trial, whose liberal inclusion criteria mean that concomitant upper 
limb disorders may have contributed to the elbow pain, and so influenced PRTEE scores. In this 
sense, the questionnaire was being applied to a broader population than its name suggests. 
However, we would argue that since tennis elbow often presents clinically with other upper 
quadrant problems, testing the questionnaire with this broader population assesses its value in a 
realistic context. Several other studies  evaluating the measurement properties of the PRTEE have 
not excluded participants with common upper limb co-morbidities such as radiculopathy or radial 
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nerve involvement13, 15, 32, and it has also been  used with different groups altogether, for instance 
those undergoing arthroplasty33. 
 
Objections have been raised regarding the retrospective use of global change measurements as 
anchors for determining responsiveness34: recall bias may mean that change scores correlate with 
present status, and the validity and reliability of a subjectively-rated GCS is very difficult to evaluate. 
Empirically derived data in a variety of clinical contexts suggests that the method does have external 
validity35, but comparisons with MCID values derived using other methods are required to build 
confidence in the interpretation of PRTEE score changes.  
 
It has been argued that responsiveness studies should be prospective, based on reasonable 
assumptions about whether and what kind of change if expected in the sample36. Although this 
analysis was retrospective, it used data from a study in which such differences were expected: the 
hypothesis of the trial, based upon previous studies, was that some types of microcurrent would be 
more effective than others. Nevertheless the results of this analysis require corroboration by other, 
prospectively designed  studies. 
 
Conclusions 
This study has provided estimates of the changes in PRTEE scores that are required to judge whether 
significant changes have occurred in symptoms experienced by patients with tennis elbow. For a 
group using the questionnaire, mean PRTEE score reductions of at least 11 points - or an 
improvement of 37% on the mean baseline score -  is necessary to consider that a substantial 
improvement has taken place. Using a less stringent criterion, falls of 7 points or 22% of the baseline 
score can be interpreted as indicating a limited but meaningful improvement. The value of separate 
ratings for pain and function in this instrument, and used with this population, is open to question. 
Until this matter is resolved, the total score may be of value in estimating symptom severity. The 
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questionnaire may have lower sensitivity to change when used with respondents who are 
symptomatic in the non-dominant arm.
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Table 1: baseline characteristics of participants.  
Sex 30 male, 27 female 
Age  - mean (range) 53 (40-69) years 
Arm dominance 10 left, 46 right, 1 ambidextrous 
Symptomatic arm 13 left, 39 right, 5 bilateral 
Number with dominant arm symptomatic 46 (80%) 
Symptom duration – median (range) 13 (3-240) months 
PRTEE Pain sub-scale – mean (range)  21 (6-48) / 50 
PRTEE Function sub-scale – mean (range) 18 (2-42) / 50 
PRTEE Total score – mean (range) 39 (13-81) / 100 
  
Table 2: AUC analysis and cut-off values for PRTEE score changes  
 Clinical significance set at GCS ≥ 1 Clinical significance set at GCS ≥ 2 
Area under curve 
(95% CI) 
Cut-off value Area under curve 
(95% CI) 
Cut-off value 
Absolute change in 
pain score / 50 
0.84 (0.74 -0.94) 4 0.8 (0.68-0.92) 6 
Percentage change 
in pain score 
0.81 (0.70-0.93) 20% 0.82 (0.70-0.94) 35% 
Absolute change in 
function score / 50 
0.83 (0.72-0.93) 3 0.83 (0.73-0.94) 6 
Percentage change 
in function score 
0.78 (0.65-0.91) 25% 0.81 (0.69-0.93) 40% 
18 
Absolute change in 
total score / 100 
0.86 (0.77-0.95) 7 0.83 (0.72-0.94) 11 
Percentage  change 
in total score  
0.83 (0.72-0.93) 22% 0.86 (0.73-0.96) 37% 
 
 
Table 3: MCID values for subgroups with different PRTEE total scores at baseline 
 Cut-off value 
 Baseline total score  
< 40/100 
Baseline total score  
≥ 40/100 
Absolute change in total score / 100 7 21 
Percentage change in total score  35% 40% 
 
 
 
 
Figure 1: Change in PRTEE total score between assessments for each Global Change Score 
 
